| dc.contributor.author | External author(s) only | |
| dc.date.accessioned | 2021-07-23T16:47:08Z | |
| dc.date.available | 2021-07-23T16:47:08Z | |
| dc.date.issued | 2021-03 | |
| dc.identifier.citation | Clarke, P.M., Roope, L.S.J., Loewen, P.J., Jean-Francois Bonnefon, Alessia Melegaro, Jorge Friedman, Mara Violato, Adrian Barnett & Raymond Duch. Public opinion on global rollout of COVID-19 vaccines. Nat Med 27, 935–936 (2021). | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/872 | |
| dc.description.abstract | To the Editor—Vaccination programs for COVID-19 in ‘high-income countries’ (HICs) have benefited from their ability to secure contracts for preferential supply for several vaccines1. For the rest of the world, vaccine access is much less certain. Although leaders of G20 nations have pledged to ensure fair distribution of vaccines against COVID-19 worldwide, substantial challenges remain. The COVAX Facility aims to ensure that all countries will have equal access to doses and can compete with HICs to acquire doses, but some low-income countries may need to wait until at least 2022 before even the most vulnerable 20% of their populations are vaccinated2 | en |
| dc.description.sponsorship | Supported by the NIHR | en |
| dc.description.uri | https://doi.org/10.1038/s41591-021-01322-9 | en |
| dc.language.iso | en | en |
| dc.subject | COVID-19 | en |
| dc.subject | Vaccinations | en |
| dc.title | Public opinion on global rollout of COVID-19 vaccines | en |
| dc.type | Article | en |